Canopy Growth Corporation (CGC) Fair Value & Analysis
Healthcare · US · Market cap $434M
Canopy Growth Corporation
CGC · US
Fair value as of: Jul 15, 2026
From 1 valuation models · updated today
Share price −4.1% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.8570 – $1.92 · fair‑value band $0.3485 – $0.6970 · the $0.9587 price screens above the $0.4675 fair value. As of Jul 15, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Canopy Growth Corporation (CGC) currently trades at $0.9587, while our model-based Fair Value estimate is $0.4675 — implying the stock looks roughly 51.2% overvalued today. We read business quality at 18/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Canopy Growth Corporation generated revenue of $285M at a net margin of -92.4%. Revenue grew 9.6% year over year. It earns a return on equity of -44.4%. Net debt stands at $235M. Fundamentals as of Jul 15, 2026
Our scenario range runs from $0.3485 (bear case) to $0.6970 (bull case); at $0.9587, the current price sits above that range. The share trades about 60% below its 52-week high and 14% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside — at -51%, CGC screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 15, 2026. TTM = trailing twelve months.
About the company
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works. The company offers dried flower and pre-rolled joints; extracts and concentrates, such as softgel capsules; cannabis edibles, including gummies; cannabis vapes; and oils, beverages, concentrates. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Wana, and Claybourne brands, as well as DOJA, LivRelief, Ace Valley, and Vert brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Canopy Growth Corporation reported revenue of $269M in FY2025 versus $547M in FY2021, a compound −16.2%/yr. Reported net income was −$598M in FY2025.
Is CGC fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| PharmaEssentia Corporation 6446 | 934.00 TWD | 365.87 TWD | -61% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,464 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,377 | ₹628.39 | -54% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,272 | ₹720.15 | -43% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Canopy Growth Corporation (CGC) undervalued?
What is the fair value of CGC?
What is the quality score of CGC?
What is the revenue of Canopy Growth Corporation (CGC)?
What is the net profit margin of CGC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Canopy Growth Corporation analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.